Skip to content

BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential

Diagnostic Significance of BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07416500
Enrollment
301
Registered
2026-02-18
Start date
2024-09-01
Completion date
2025-06-30
Last updated
2026-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Breast Lesions of Uncertain Malignant Potential (B3 Lesions)

Keywords

BRCA1, RASSF1A, PTEN

Brief summary

This prospective interventional diagnostic study evaluates the clinical utility of methylation analysis of BRCA1, RASSF1A and PTEN genes in breast lesions of uncertain malignant potential (B3 lesions). Women with suspicious non-palpable breast lesions undergo standard diagnostic procedures including clinical examination, imaging assessment, and image-guided core needle biopsy when indicated. As part of the study protocol, breast tissue samples are prospectively assigned to additional molecular diagnostic testing using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). The study evaluates whether gene promoter methylation status improves diagnostic assessment by comparing methylation results with final histopathological diagnosis.

Detailed description

Breast cancer is the most common malignancy in women. Epigenetic alterations, particularly DNA promoter methylation of tumor suppressor genes, play an important role in breast carcinogenesis and may occur early in disease development. This single-center prospective interventional diagnostic study is conducted at the Institute of Oncology Ljubljana. Participants are women with suspicious non-palpable breast lesions referred through the Slovenian national screening program DORA or other diagnostic pathways. All participants undergo standard diagnostic work-up, including: * clinical breast examination, * breast imaging (mammography and/or ultrasound), * image-guided core needle biopsy when indicated. Breast tissue samples obtained during biopsy or surgical excision are prospectively assigned to additional molecular testing using MS-MLPA to determine methylation status of BRCA1, RASSF1A and PTEN. Histopathological classification includes: * benign lesions, * lesions of uncertain malignant potential (B3 lesions), * malignant lesions. The primary objective is to evaluate the diagnostic performance of methylation analysis compared with histopathological diagnosis. Statistical analysis will be performed using SPSS and GraphPad Prism. Sensitivity, specificity, positive predictive value, and negative predictive value will be calculated. Group comparisons will be performed using chi-square test or Fisher's exact test. Statistical significance is defined as p \< 0.05.

Interventions

DIAGNOSTIC_TESTMS-MLPA Methylation Analysis

Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) is performed on breast tissue samples obtained during routine diagnostic procedures. The assay determines promoter methylation status of BRCA1, RASSF1A and PTEN. Results are compared with the final histopathological diagnosis to evaluate diagnostic performance.

Sponsors

Institute of Oncology Ljubljana
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

All participants undergo standard diagnostic procedures and molecular methylation analysis (MS-MLPA) of BRCA1, RASSF1A and PTEN in breast tissue samples.

Eligibility

Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Female participants aged 40 years or older * Suspicious non-palpable breast lesion referred for diagnostic evaluation at the Institute of Oncology Ljubljana * Undergoing image-guided core needle biopsy or surgical excision as part of standard diagnostic work-up * Availability of sufficient breast tissue sample for methylation analysis Signed written informed consent

Exclusion criteria

* Contraindications to standard diagnostic procedures * Insufficient tissue sample for molecular analysis * Withdrawal of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic Performance of BRCA1, RASSF1A and PTEN Methylation AnalysisUp to June 2025Sensitivity (%), specificity (%), positive predictive value (%) and negative predictive value (%) of methylation status determined by MS-MLPA for detection of malignant breast lesions compared with histopathological diagnosis.

Countries

Slovenia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026